Human prothrombin was acetylated to produce a modified prothrombin that upon activation by platelet-bound prothrombinase generates a form of thrombin that does not activate platelets but retains its amidolytic activity on a chromogenic peptide substrate. If normal prothrombin is used in such an assay, the thrombin that is generated activates the platelets in a feedback manner, accelerating the rate of thrombin generation and thereby preventing accurate measurement of the initial platelet procoagulant activity. Acetylation of prothrombin was carried out over a range of concentrations of sulfo-N-succinimidyl acetate (SNSA). Acetylation by 3 mM SNSA at room temperature for 30 min at pH 8.2 in the absence of metal ions produced a modified prothrombin that has <0.1% clotting activity (by specific prothrombin clotting assay), but it is activated by factor Xa (in the presence of either activated platelets or factor Va ؉ anionic phospholipid) to produce thrombin activity that is measurable with a chromogenic substrate. Because the feedback action on the platelets is blocked, thrombin generation is linear, allowing quantitative measurement of the initial platelet activation state.
Platelets are a major contributor to the pathology of thrombosis, particularly arterial thrombosis, where they form the bulk of thromboembolic occlusions. It is not clear to what extent such platelets are activated in vivo by the ordinary hemostatic pathway and initiated by exposure of the subendothelium and to what extent by other causes, such as exposure to shear stress (1, 2) . It is known, however, that mechanical stress can activate platelets, and this is particularly relevant to studies of the effects of biomedical devices-chiefly prosthetic valves-on platelets and the increased thrombotic risk in patients with such valves (3, 4) . To measure the effect of these devices on platelets in vitro, platelet aggregation has often been used, but this represents a final event in platelet activation, and it is difficult to quantify.
Platelet activation causes the exposure of two critical factors involved in the formation of thrombin. (i) Anionic phospholipid-mainly phosphatidylserine-is transferred from the inner leaflet of the cell membrane to the outer leaflet and there supports the binding and activation of the vitamin K-dependent proteins of coagulation: factors VII, IX, and X and prothrombin (see Ref. 5 for a general review of the coagulation pathways). (ii) Factor V, which is present in the ␣-granules of the platelets, is concomitantly activated and the resulting factor Va, which is a required cofactor for prothrombin activation by factor Xa, is expressed on the membrane surface. Thus, activated platelets provide both the major cofactors required for prothrombin activation by factor Xa. The complete complex, of factor Xa ϩ Va ϩ anionic phospholipid, has been called the prothrombinase complex. A number of investigators, led by Rosing and Zwaal and their colleagues (6, 7) , have taken advantage of the platelets' providing these activities in using the kinetics of prothrombin activation in the presence of platelets as a measure of their "procoagulant" activity and by extension of their activation state. However, the use of this assay is problematic because the enzyme generated and measured in the assay-thrombin-is a potent platelet activator. As the platelets become activated, or further activated, during the assay, the thrombin generation rate increases, and measurement of the initial rate of thrombin generation is often unreliable.
We need here a prothrombin species that is activated by prothrombinase, but generates an abnormal thrombin that (i) does not activate platelets but (ii) can still be detected. Such prothrombin species do exist, both as very rare congenitally mutant proteins and as molecules produced by chemical modification of prothrombin. Landaburu and Seegers (8) demonstrated nearly 40 years ago that acetylation of prothrombin produces a protein that can be activated by prothrombinase, but the acetylated thrombin that is generated is inactive on fibrinogen, even though it retains activity on small substrates like amino acid or peptide esters and amides. White and colleagues (9) chemically modified a small number of the lysine residues of human ␣-thrombin using pyridoxal 5Ј-phosphate and showed that the modified enzyme is defective not only in fibrinogen cleavage but also in platelet aggregation. Similarly, Morrison (10) observed that reaction of prothrombin with a nucleophilic reagent (dichlorotriazinylaminofluorescein) produced a molecule that was activated normally, but generated a defective thrombin with Ͻ5% activity on fibrinogen. Two congenital mutants of prothrombin with very similar properties were described over the same period, the prothrombins Metz (11) and Quick I (12, 13) . Both can be activated by the prothrombinase complex, but the thrombin species produced, just as with chemically modified protein, are defective in their action on both fibrinogen and platelets. Interestingly, a chemical-modification study of another clotting zymogen has shown that this behavior is not unique to prothrombin: acetylation of factor X under mild conditions produces a molecule that is activated normally, but the acetylated factor Xa generated has no activity on two macromolecular substrates that were tested, prothrombin and factor VIII (14, 15) .
We demonstrate in this report that acetylated prothrombin is activated by the prothrombinase complex to yield an enzyme that is inactive on fibrinogen, but retains activity on a peptide p-nitroanilide substrate. Moreover, thrombin generation from acetylated prothrombin by platelet-bound prothrombinase is linear with time, strongly suggesting that the acetylated thrombin produced upon activation is also inactive on platelets, allowing the quantitative measurement of initial prothrombinase activity-and hence the activation state-of the platelets provided.
MATERIALS AND METHODS
Materials. Bovine serum albumin (BSA 1 ; fatty acid free, fraction V), calcium ionophore A23187, phosphatidylserine, phosphatidylcholine, and common reagentgrade chemicals were obtained from Sigma Chemical (St. Louis, MO). N-Tris(hydroxymethyl)methylglycine (Tricine) and N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (Hepes) were from Calbiochem-Behring (San Diego, CA). The chromogenic amide substrate for thrombin was Chromozym-TH (tosyl-Gly-L-Pro-L-Arg-p-nitroanilide), from Boehringer-Mannheim (IN). BioGel A-15M was obtained from Bio-Rad Laboratories (Richmond, CA). Sulfo-N-succinimidyl acetate (SNSA) was from Pierce Chemical (Rockford, IL). Phosphatidylserine and phosphatidylcholine were prepared as a sonicated 30:70 (PS:PC) mixture at a stock concentration of 2 mg/ml in 0.1 M NaCl/0.05 M Tris/ HCl, pH 7.5.
Prothrombin-deficient plasma for clotting assays was prepared by the following method. (The older method of BaSO 4 adsorption of oxalated plasma is not applicable to modern clotting instruments, because the calcium oxalate precipitate formed upon addition of CaCl 2 in the assay interferes with the optical detection system; hence, this preparation based on citrated plasma.) Blood was collected into 1/100 vol 40% sodium citrate and centrifuged at 2500g for 15 min to yield plasma. One-twentieth volume of 1.5 M BaCl 2 was added to the plasma on ice, the mixture was stirred for 15 min, and the barium citrate precipitate was removed by centrifugation (15,000g for 10 min). To remove the excess free Ba 2ϩ in the plasma, Na 2 SO 4 was added to a concentration of 70 mM and stirred for 10 min on ice. The resulting BaSO 4 was removed by centrifugation. Finally, sodium citrate was added to a concentration of 10 mM to mimic the free citrate concentration in ordinary congenitally deficient plasma.
Human factor X was prepared by the method of Morrison and Jesty (16) , and human factor Xa by the method of Jesty and Nemerson (17) . The concentration of factor Xa was determined by reference to a standard factor Xa that had been assayed by titration with pure bovine antithrombin III. Bovine factor Va was prepared as described by Martin and Jesty (18) . Human ␣-thrombin was prepared by a modification of the method of Fenton et al. (19) using cation-exchange chromatography on CM-Sephadex.
Acetylation. Prothrombin (10 M) was dialyzed against 0.1 M NaHCO 3 (pH 8.2) in the absence of divalent metal ions and then acetylated with SNSA at room temperature for time courses up to 90 min, using reagent concentrations of 0.1, 0.3, 1, 3, and 10 mM. The reaction with the reagent was stopped by the addition of 1/10 vol 0.5 M Tris-HCl, pH 8. The product was assayed using two methods: (i) The clotting activity was measured by a one-stage prothrombin clotting assay using barium-adsorbed prothrombin-deficient plasma (see above) containing 0.1 mg/ml soybean lecithin and bovine factor Xa (0.1 g/ml) as activator. The assay was standardized with purified human prothrombin over the range 0.3-150 nM. (ii) Acetylated or control prothrombin (100 nM) was activated by factor Xa in the presence of bovine factor Va and PS:PC, and the rate of thrombin generation was determined by chromogenic assay (see below).
Isolation of platelets. Blood (100 ml) was drawn by venipuncture from an informed healthy volunteer into 1 ml of 40% trisodium citrate and centrifuged at 400g for 10 min to obtain platelet-rich plasma. The platelets were separated from the plasma by gel filtration at room temperature of a 15-ml sample in a 240-ml column of Bio-Gel A-15M, 50 -100 mesh, equilibrated in buffer containing 0.1% BSA, 5 mM glucose, 135 mM NaCl, 2.7 mM KCl, 0.5 mM NaH 2 PO 4 , 1 mM MgCl 2 , and 10 mM Hepes-NaOH, pH 7.4 (20) . The resulting plasma-free platelets were counted with a Coulter ZM counter (Coulter, Hialeah, FL). Platelets isolated in this way were used within 8 h of their isolation. It should be noted that, while gel filtration is a physically mild method of isolation, no special procedures were used to further reduce the activation of platelets during the procedure.
Assay of prothrombin activation. This was performed with p-nitroanilide substrate for thrombin, Chromozym-TH, in a discontinuous amidolytic assay. Incubations were performed at 37°C in a volume of 250 l containing HBS/BSA (0.1% BSA in 0.13 M NaCl/20 mM Hepes-NaOH, pH 7.4). Each incubation contained normal or acetylated prothrombin (100 nM), 50 pM factor Xa, either 10 M PS:PC or platelets (10,000/l), and 5 mM CaCl 2 . Timed samples, 20 l, were removed into tubes containing 180 l of 10 mM EDTA in HBS/ BSA, which stops further prothrombin activation. The diluted samples, 20 l, were then assayed for thrombin activity in microplate wells containing 50 l 1 mM Chromozym-TH plus 50 l 50 mM Tricine-HCl, pH 8.3. Absorbance at 405 nm was measured at 10-s intervals, and the data were then fitted by iterative polynomial regression to obtain an initial slope, ⌬A 405 /min, in each well. The fitting method, described by Neuenschwander and Jesty (20) , is probably not necessary for ordinary analysis of platelet data, but it accounts accurately for minor nonlinearity caused by the reduction in substrate concentration during the assay. Thrombin concentrations in each sample were obtained by reference to a pure preparation of thrombin. The initial rates of thrombin generation in each experiment were generally determined from secondary plots of the course of thrombin generation by linear regression. However, in the case of the most rapid activations, which showed a significant reduction in rate during even a short incubation course, good fits were obtained by assuming the kinetics to be approximately first order with respect to prothrombin concentration (see Fig.  1 ). These data were therefore fitted to a single exponential, E t ϭ E max (1 Ϫ e Ϫkt ), which on differentiation gives the initial slope as E max k.
To this point the assay of platelet procoagulant activity has not been formally standardized. This is particularly important given the variability in the acetylated prothrombin substrate. In the course of this study we have used two checks of the assay, either of which might be developed as a standardization procedure: (i) Heavily sonicated platelets (e.g., 25 W for 1 min at 0°C) provide a source of platelet membrane vesicles that may be assumed to be essentially randomized as regards the bilayer distribution of anionic phospholipid. This has the disadvantage of the significant variation in platelets among individual donors and the fact that the activation state of the platelet factor V in such a preparation is unknown. (ii) A rather more reliable prothrombinase standard uses purified factor Va and PS:PC vesicles, but this is less closely related to platelets.
RESULTS

Prothrombin acetylation conditions.
For use as a substrate in a prothrombinase assay of platelet activation state, optimally acetylated prothrombin would be activated at normal rates by the prothrombinase complex, but produce a thrombin species that (i) has zero activity on platelets and (ii) has full amidolytic activity against a p-nitroanilide peptide substrate. Testing the first requirement would require the generation and purification of thrombin from prothrombin modified under each acetylation condition, which was not feasible with the variety of conditions being tested. As a surrogate, we used the clotting activity as a measure of the activity of the generated thrombin on macromolecular substrates (in the clotting assay, the thrombin substrate is fibrinogen), and, by extension, on platelets (9) . The second requirement was tested by activating each preparation of acetylated prothrombin under standard conditions with exogenous complete prothrombinase complex (factors Xa ϩ Va ϩ PS:PC vesicles) and measuring the generation of thrombin in a chromogenic assay. Table 1 shows the results of these assays after acetylation of prothrombin with varying concentrations of SNSA in 0.1 M NaHCO 3 (pH 8.2) at room temperature for 30 min. The activity measured by clotting assay is expressed as a fraction of the activity of unmodified prothrombin. The generated chromogenic activity is expressed in terms of the rate of generation of thrombin chromogenic activity, determined by assay of discontinuous timed samples from mixtures containing prothrombinase complex and (modified) prothrombin. It should be noted that all the acetylated prothrombin preparations, except that made with 10 mM SNSA, generate more amidolytic activity than does normal prothrombin. Such increases in the activity of acylated clotting proteases on ester and amide substrates have been previously reported (8, 9, 14) . In the range 1-3 mM SNSA (30-min treatment, pH 8.2, room temperature), essentially total inactivation of clotting activity occurs (Ն99.8%), while generation of chromogenic activity remains satisfactory in all cases.
However, although acetylation causes no reduction in the rate of activation of prothrombin by factor Xa ϩ Va ϩ PS:PC, when activated platelets are used in place of factor Va ϩ PS:PC there is a large reduction in the activation rate of the acetylated molecule (see below).
Activation of normal prothrombin in the presence of unactivated and activated platelets. The generation of thrombin chromogenic activity from normal prothrombin in the presence of factor Xa plus unactivated and activated platelets, 2 ϫ 10 7 /ml, is shown in Fig. 1 . A high concentration of calcium ionophore A23187 was used as the platelet activator. The platelet count was chosen to ensure that the platelets are limiting in providing prothrombinase activity; in other words, the rate of thrombin generation is a measure of the platelet contribution. Under these conditions activated platelets provide both the required cofactors: factor Va and anionic phospholipid membrane. In the absence of prior activation of the platelets (Fig. 1, E) , the generation of thrombin shows a characteristic lag phase, indicating a requirement for feedback activation of the platelets during the incubation. That the lag represents a requirement for platelet activation is confirmed by prior treatment of the platelets with calcium ionophore (Fig. 1, F) .
Activation of acetylated prothrombin in the presence of platelets. Figure 2 shows the corresponding activa- Note. Prothrombin was acetylated with SNSA at pH 8.2 at room temperature for 30 min. Samples were assayed by clotting assay and by chromogenic measurement of the rate of activation by the prothrombinase complex (factor Xa ϩ Va ϩ PS:PC).
FIG. 1.
Activation of normal prothrombin in the presence of platelets, unactivated or activated with calcium ionophore A23187. Platelets were incubated for 2 min at 37°C with prothrombin and CaCl 2 , plus (F) and minus (E) 10 M A23187. Factor Xa, 1/20 vol, was then added to start prothrombin activation. The final concentrations of each reactant in the activation phase were as follows: 10,000 platelets/l, 100 nM prothrombin, 5 mM CaCl 2 , and 50 pM factor Xa. Samples, 20 l, were removed at the times shown into 180 l of 10 mM EDTA in HBS/BSA. Samples of each of these dilutions, 20 l, were assayed for thrombin chromogenic activity. The thrombin concentrations, derived from a standard of pure ␣-thrombin, represent the thrombin amidolytic level in the prothrombin-activation incubation.
FIG. 2.
Activation of acetylated prothrombin in the presence of platelets, unactivated or activated with calcium ionophore A23187. The experimental details are as described in the legend to Fig. 1 , except that acetylated prothrombin was used. Thrombin concentrations are derived from a standard of normal (nonacetylated) ␣-thrombin.
tion of acetylated prothrombin under the same conditions. The first thing to note is the large reduction in the rate of generation of chromogenic activity compared with that in Fig. 1 . This is in direct contrast to the full rate of thrombin generation that is obtained when exogenous factor Va and PS:PC, rather than platelets, are used to activate acetylated prothrombin ( Table 1 ). The cause of this is unknown, but it strongly suggests that the interaction of prothrombin with activated platelets is highly dependent on another site on the molecule that is modified by acetylation. This is addressed further in the Discussion. Despite the lower reactivity, the effect of acetylation is clear: In the absence of platelet activation (Fig. 2, E) , the generation of thrombin remains linear with time. By comparison with Fig. 1 , it is clear that platelet activation is not occurring during the assay. However, prior platelet activation with calcium ionophore enables a fivefold increase in the thrombin generation rate.
Thrombin activation of platelets. To this point the results suggested that feedback activation of the platelets by thrombin was responsible for the increasing rate of thrombin generation in the platelet-dependent activation of normal prothrombin, observed in Fig. 1 . To confirm this, experiments were performed on platelets pretreated with thrombin (Fig. 3) . At 10 nM thrombin, the lag phase in thrombin generation is substantially shortened, but not quite abolished, while at 50 nM, no lag phase is evident. (Note that the thrombin activities at zero time in this figure are due to the thrombin used to preactivate the platelets in each case.) It should also be noted that the final rates of thrombin generation in each experiment are nearly identical, showing that the same prothrombinase activity is obtained in each, whether activation by thrombin occurs in situ during the incubation or by exogenous treatment with enzyme.
Thrombin-activated platelets on acetylated prothrombin. Figure 4 essentially mimics the use of the assay in measurements of platelet procoagulant activity, showing the activation of acetylated prothrombin in the presence of untreated and thrombin-treated platelets. As before, the reduction in thrombin generation rate when acetylated prothrombin is activated with platelet-bound prothrombinase is clear. Nonetheless, activation remains easily measurable, and no nonlinearity of thrombin generation is evident in any incubation. We conclude that acetylation of prothrombin indeed blocks the feedback activation of platelets during these assays, allowing a quantitative measurement of procoagulant activity of the platelets.
DISCUSSION
The method devised here derives from two existing methods: (i) The prothrombinase assay of the procoagulant state of both erythrocytes and platelets is well described (7, 18, 21) . In studies of erythrocytes factor Va is provided in the assay and the activity corresponds with exposure of anionic phospholipid. In the measurement of platelet activation, both factor Va and anionic phospholipid can be provided by the platelets, so factor V need not be provided. (ii) In the case of platelets, however, the method cannot easily be used unmodified because the small amounts of thrombin   FIG. 4 . Activation of acetylated prothrombin in the presence of platelets, unactivated or thrombin-activated. The experimental details are as described in the legend to Fig. 3 , except that acetylated prothrombin was used. Thrombin concentrations were derived from a standard of normal (nonacetylated) ␣-thrombin.
FIG. 3.
Activation of normal prothrombin in the the presence of platelets, unactivated or thrombin-activated. Platelets (10,000/l) were incubated for 5 min in the presence of prothrombin, of prothrombin and CaCl 2 , as described in the legend to Fig. 1 , plus ␣-thrombin at concentrations of 0 (E), 10 nM (F), and 50 nM (ᮀ). Factor Xa was then added to start prothrombin activation. Samples were removed and assayed for thrombin generation as described in the legend to Fig. 1. produced in the early phases of the assay feed back and further stimulate the platelets. For a more reliable assay, a modified prothrombin is needed that (i) is activated at normal or near-normal rates by the prothrombinase complex and (ii) produces thrombin that cannot activate platelets. The use of acetylated prothrombin for this purpose is based on a very similar modification of the clotting zymogen factor X, in which acetylation was used to block the proteolytic activity of generated factor Xa (14) , and thereby enabled studies of the activity of unactivated factor VIII in factor X activation (15) .
Extrapolating from the results of White et al. (9) , who used pyridoxal phosphate to modify lysine residues in thrombin, it seems likely that acetylation under the conditions used modifies a binding site in the thrombin domain of prothrombin that is distant from the enzyme's active site (an exosite), but which is required for enzymic activity on macromolecular substrates such as fibrinogen and the platelet thrombin receptor. In contrast, judging by the near-normal rates of generation of thrombin amidolytic activity on small peptide substrates, we conclude that acetylation does not significantly alter the activation of prothrombin by factor Xa; i.e., the interactions of acetylated prothrombin with purified components of the prothrombinase complex-factor Xa, factor Va, and anionic phospholipid-appear to be essentially normal.
However, we observed an additional effect of acetylation: Whereas acetylated prothrombin is activated normally in the presence of purified phospholipid and factor Va, its activation rate is significantly reduced when activated platelets are the source of the prothrombinase complex. This suggests that acetylation may also affect a site through which prothrombin interacts with activated platelets, probably separate from the site that is responsible for the reduction of thrombin activity on macromolecular substrates. Two sets of observations in the literature are relevant. First, it is known that acetylation of (bovine) prothrombin modifies three key residues in the fragment-1 (NH 2 -terminal) region of the molecule: specifically, the aminoterminal alanine and two particularly reactive residues in the fragment-1 kringle: His-96 and the carbohydrate-linked Asn-101 (22) (23) (24) . It is possible that one or more of these residues are modified under our acetylation conditions and are involved in a platelet-specific interaction. The second perhaps-relevant observation points to a possible role of the major platelet integrin ␣ IIb ␤ 3 (GPIIb/IIIa) in the activation of prothrombin (25, 26) and specifically to an interaction between this receptor and an Arg-Gly-Asp (RGD) sequence (residues 560 -562, human prothrombin precursor numbering) in the still-latent catalytic domain of prothrombin. This sequence is immediately Nterminal to Ser-568, which becomes the active-site serine of thrombin, and in fact in the active enzyme the Asp residue of the RGD sequence provides the negative charge at the bottom of the trypsin-family S1 binding pocket. Immediately N-terminal to the RGD sequence is a Lys residue, Lys-559, and it is tempting to postulate that modification of this residue might cause the defective interaction of acetylated prothrombin with platelets.
The method described in this report enables the quantitative measurement of the activation state of platelets by a simple and sensitive method. As mentioned in the Introduction, one area in which it will be particularly useful is the study of the effects of biomedical devices such as pumps and prosthetic valves on platelets in flow experiments in vitro. Since the method requires significant manipulation in the separation of the platelets from the blood plasma (to avoid clot formation and thrombin inhibition during the assay), it is not so well suited to examination of the activity state of patients' platelets.
